DDInter1335 DDInter172
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Omacetaxine mepesuccinate {u} (Compound) binds {v} (Gene) RPL3
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DUSP8
Omacetaxine mepesuccinate {u} (Compound) downregulates {v} (Gene) B4GAT1
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rituximab
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Risankizumab
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Indomethacin
Omacetaxine mepesuccinate {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Omacetaxine mepesuccinate (Compound) binds RPL3 (Gene)
Omacetaxine mepesuccinate (Compound) upregulates DUSP8 (Gene)
Omacetaxine mepesuccinate (Compound) downregulates B4GAT1 (Gene)
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Rituximab
Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Indomethacin
Omacetaxine mepesuccinate may lead to a major life threatening interaction when taken with Avapritinib